Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome

计划入组 30 人 · 首次发布于 2024 年 7 月 3 日

Safety and Tolerance Study of IBI355 in Health Volunteers

计划入组 53 人 · 首次发布于 2023 年 10 月 31 日

Safety and Tolerability of IBI355 in Healthy Volunteers

计划入组 32 人 · 首次发布于 2024 年 5 月 16 日

IBI355

UX- SP001

IBI356

Innovent and Spero Strike $1.1 Billion Deal for Third-Generation Anti-CD40L Antibody Targeting IgG4-RD and Sjögren's Disease

Spero Therapeutics Secures $105 Million Non-Dilutive Royalty Financing to Advance Anti-CD40L Antibody SP001

Spero Therapeutics Appoints Dr. Debra Jeske Zack as CMO to Lead Phase 2-Ready Anti-CD40L Antibody SP001